In patients 5 to 11 years of age, the difference in LS mean change in FEV 1 (0 to 4 hours) for Breo Ellipta 50/25mcg compared with fluticasone furoate 50mcg was 73mL (95% CI, 28-118).

BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta 2-agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).It is indicated for the ...

GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of ...

BREO™ ELLIPTA™, is the proposed proprietary name for FF/VI 100/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate "FF" and the long acting bronchodilator (LABA ...

Breo Ellipta (FF/VI 100/25 μg) is already approved in the United States for long-term, once-daily, maintenance treatment of airflow obstruction and for reducing exacerbations in patients with ...

Analysts figure Breo for a blockbuster in the U.S., with peak sales at around $1.3 billion. | The FDA granted approval to GlaxoSmithKline's new respiratory drug Breo Ellipta.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease , is now available to pharmacies throughout the ...